Clinician dossier · cetosomes.com

Cetosome® platform: patents, studies & specifications

Back

1. Patent family

US 9,084,818 B2Topical dermal delivery compositions using self assembling nanoparticles with cetylated components. Cymbiotics, Inc. Filed 15 Feb 2013, granted 21 Jul 2015.
US 8,394,759 B2Transdermal delivery of medicaments with combinations of cetylated fatty ester penetrant complexes. Cymbiotics, Inc. Priority 21 Nov 2008, granted 12 Mar 2013.

2. Platform specifications

Composition≥40% aqueous phase; 4–20% of ≥4 cetylated/stearyl esters; cetyl/stearyl alcohols at ≥1:3 molar ratio to esters; 1–20% surfactant; 2–30% polar solvent
Particle diameter60–850 nm measured (often bimodal); claims 30 nm–5 µm
Zeta potentialClaimed −20 to −100 mV (or +20 to +100 mV); −22 to −55 mV measured across formulations
pH rangeAqueous phase pH 4–10; stable over a wide pH range
StabilityReal-time 25 °C / 65% RH: 26 months (CLDC0704), 18 months (RDNC1209); 6 months real-time and 40 °C / 75% RH (DPNC1008)
MechanismCrosses the stratum corneum without permanent barrier disruption; disassembles into smaller penetration units for gradual release

3. Clinical studies

StudyDesignKey findings
Sattur et al. Cureus 2023;15(10):e46568Randomised, open-label; cetosomal vs alcohol-based 5% minoxidil; 16 weeks; 80 enrolled, 40 analysedAEs 9% vs 41% (p = 0.02); QoL improved in 78% vs 41% (p = 0.02); efficacy differences not significant
Kerure et al. Cureus 2023;15(7):e41681Retrospective, 66 centres; n = 261; cetosomal minoxidil ± finasteride 0.1%; 16 weeks1 treatment-related AE (0.3%); tolerability "excellent" 64–69%; PGA significant-to-excellent 52–68%
Patent example (RDNC1209)Phase 2 clinical experience, n = 100, chronic discogenic back painSustained relief for several hours; no side effects observed (patent-reported, not peer-reviewed)

4. Limitations

  • Both peer-reviewed studies concern minoxidil; data for retinoids, acids and pigmentation actives are mechanistic, not yet trial-based.
  • Small or retrospective designs; 50% attrition in the randomised study; industry-affiliated authors.
  • Patent examples are not peer-reviewed. Some pharmacokinetic data are from animal (rabbit) models.

Full reference library

  1. Barathur RR, Bookout JB (assignee: Cymbiotics, Inc.). Topical dermal delivery compositions using self assembling nanoparticles with cetylated components. US Patent US 9,084,818 B2. 2015.Filed 15 Feb 2013; granted 21 Jul 2015. Claim 1 specifies nanoparticle zeta potential of −20 to −100 mV (or +20 to +100 mV). Measured particle diameters of 60–850 nm; claimed physical dimensions 30 nm–5 µm.
  2. Barathur RR, Bookout JB (assignee: Cymbiotics, Inc.). Transdermal delivery of medicaments with combinations of cetylated fatty ester penetrant complexes. US Patent US 8,394,759 B2. 2013.Priority 21 Nov 2008; filed 29 Oct 2009; granted 12 Mar 2013. Foundational cetylated-fatty-ester penetrant work, incorporated by reference into US 9,084,818 B2.
  3. Kerure A, Ghalla M, Mahajan S, Dhoot D, Barkate H. Real-World Effectiveness, Safety, and Tolerability of Cetosomal Minoxidil 5% Alone and a Fixed Drug Combination of Cetosomal Minoxidil 5% With Finasteride 0.1% in the Management of Androgenetic Alopecia (Inbilt Study). Cureus 15(7):e41681. 2023.DOI 10.7759/cureus.41681 · PMID 37575862 · PMC10413304Retrospective, 66 centres, n = 261. Industry-affiliated authors (employees of the product's marketing company).
  4. Sattur S, Talathi A, Shetty G, Arsiwala S, Pereira R, Dhoot D. Comparative Clinical Study Evaluating the Efficacy and Safety of Topical 5% Cetosomal Minoxidil and Topical 5% Alcohol-Based Minoxidil Solutions for the Treatment of Androgenetic Alopecia in Indian Men. Cureus 15(10):e46568. 2023.DOI 10.7759/cureus.46568 · PMID 37937040 · PMC10626207Randomised, open-label, 5 centres; 80 enrolled, 40 analysed. One author employed by the product's marketing company.
  5. Bos JD, Meinardi MMHM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology 9(3):165–169. 2000.DOI 10.1034/j.1600-0625.2000.009003165.x
  6. Prausnitz MR, Langer R. Transdermal drug delivery. Nature Biotechnology 26(11):1261–1268. 2008.DOI 10.1038/nbt.1504
  7. Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes — novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. Journal of Controlled Release 65(3):403–418. 2000.DOI 10.1016/S0168-3659(99)00222-9
  8. Cevc G, Blume G. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochimica et Biophysica Acta — Biomembranes 1104(1):226–232. 1992.DOI 10.1016/0005-2736(92)90154-E
  9. Elsayed MMA, Abdallah OY, Naggar VF, Khalafallah NM. Lipid vesicles for skin delivery of drugs: reviewing three decades of research. International Journal of Pharmaceutics 332(1–2):1–16. 2007.DOI 10.1016/j.ijpharm.2006.12.005
  10. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. International Journal of Pharmaceutics 172(1–2):33–70. 1998.DOI 10.1016/S0378-5173(98)00169-0
  11. Danaei M, Dehghankhold M, Ataei S, et al. Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. Pharmaceutics 10(2):57. 2018.DOI 10.3390/pharmaceutics10020057
  12. Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles. Journal of Extracellular Vesicles 7(1):1535750. 2018.DOI 10.1080/20013078.2018.1535750
  13. US Food and Drug Administration, Center for Biologics Evaluation and Research. Public Safety Notification on Exosome Products. FDA Safety & Availability (Biologics). 2019.
  14. Feldmann RJ, Maibach HI. Regional Variation in Percutaneous Penetration of 14C Cortisol in Man. Journal of Investigative Dermatology 48(2):181–183. 1967.DOI 10.1038/jid.1967.29
  15. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery — a review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics 50(1):161–177. 2000.DOI 10.1016/S0939-6411(00)00087-4
  16. Elias PM. Stratum Corneum Defensive Functions: An Integrated View. Journal of Investigative Dermatology 125(2):183–200. 2005.DOI 10.1111/j.0022-202X.2005.23668.x
  17. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology 74(5):945–973.e33. 2016.DOI 10.1016/j.jaad.2015.12.037
  18. King S, Campbell J, Rowe R, et al. A systematic review to evaluate the efficacy of azelaic acid in the management of acne, rosacea, melasma and skin aging. Journal of Cosmetic Dermatology 22(10):2650–2662. 2023.DOI 10.1111/jocd.15923
  19. Mukherjee S, Date A, Patravale V, Korting HC, Roeder A, Weindl G. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clinical Interventions in Aging 1(4):327–348. 2006.DOI 10.2147/ciia.2006.1.4.327
  20. Bhattacharjee S. DLS and zeta potential — What they are and what they are not?. Journal of Controlled Release 235:337–351. 2016.DOI 10.1016/j.jconrel.2016.06.017
  21. Fitton A, Goa KL. Azelaic Acid: A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. Drugs 41(5):780–798. 1991.DOI 10.2165/00003495-199141050-00007

Methodology

Content is written from primary sources: granted US patent text, peer-reviewed journals indexed in PubMed or Crossref, and regulator publications. Numerical specifications are quoted exactly as reported in the cited source. Where data are illustrative models rather than measurements, the figure says so.

Conflict of interest & scope

Cetosomes.com is operated in association with parties that manufacture and dispense Cetosome®-based formulations. This site explains vehicle and delivery biophysics; it does not diagnose, treat or prescribe. Clinical decisions belong to a qualified dermatologist or physician. Research articles in the Journal carry no product or brand references.

In your routine or your clinic

Explore Cetosome® formulations

Cetosome® vehicles are dispensed through dermatology, not mass retail. The direct way to bring the technology into your routine or practice is Monoskin, the dermatological range built on the platform.

For your skin: choose a need

For your clinic

Stocking or prescribing Cetosome® formulations? Reach the clinic team, or ask our formulation desk for the literature dossier.

Opens monoskin.com in a new tab. Diagnosis and the choice of active belong to your dermatologist.